Genetic alterations predisposing to ovarian cancer, both among women in high-risk families and among patients in the general population, can be identified by positional cloning; integrating a systematic survey of genetic alterations in tumors, linkage mapping in families, physical mapping of the linked region, and comparison of sequences of candidate genes therein in tumors, patients and controls. We have successfully applied this approach to breast cancer and propose to do the same for ovarian cancer. Families with multiple cases of ovarian cancer will be identified from four cohorts and first tested for linkage to BRCA1. For families with ovarian cancer linked to 17q21, we will determine whether ovarian cancer is associated with different mutations of BRCA1 than is breast cancer; these will be compared with somatic alterations in sporadic ovarian tumors. We will evaluate epidemiologic risk factors that might distinguish ovarian cancer families with disease linked vs not linked to BRCA1. For families with ovarian cancer not linked to 17q21, we will map the critical genes by a genome-wide search, initially focusing on chromosomal regions with imbalance in ovarian tumors, and those with genes linked to predisposition to other forms of cancer also seen in the ovarian cancer families. We will identify candidate regions both from published reports of loss of heterozygosity (LOH), gene amplification, increased modes of gene expression and chromosomal alterations in ovarian tumors, and by screening malignant and benign ovarian tumors for LOH on all chromosome arms and karyotyping incident cases. The patterns of acquired mutations leading to ovarian cancer in the general population will be evaluated by identifying mutations at predisposing genes, LOH at critical regions and increased gene amplification and expression of ovarian oncogenes in the tumors of 300 previously identified patients, and 120 patients to be identified over the next four years. Correlations between genetic markers and tumor progression and outcome will also be made. Ovarian cancer is one of the most lethal cancers for women because it has been nearly impossible to detect at early, curable stages. Identifying genes critical to ovarian cancer development and progression, both in high risk families and among women generally, will pave the way for possible prevention, much earlier diagnosis and improved outcome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA060650-03
Application #
2101396
Study Section
Special Emphasis Panel (SRC (50))
Project Start
1993-08-04
Project End
1997-05-31
Budget Start
1995-06-01
Budget End
1996-05-31
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Pediatrics
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Thai, T H; Du, F; Tsan, J T et al. (1998) Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Hum Mol Genet 7:195-202
Yu, X; Wu, L C; Bowcock, A M et al. (1998) The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem 273:25388-92
Ayi, T C; Tsan, J T; Hwang, L Y et al. (1998) Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein. Oncogene 17:2143-8
Krainer, M; Silva-Arrieta, S; FitzGerald, M G et al. (1997) Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 336:1416-21
Bergstein, I; Eisenberg, L M; Bhalerao, J et al. (1997) Isolation of two novel WNT genes, WNT14 and WNT15, one of which (WNT15) is closely linked to WNT3 on human chromosome 17q21. Genomics 46:450-8
Jin, Y; Xu, X L; Yang, M C et al. (1997) Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. Proc Natl Acad Sci U S A 94:12075-80
Kirkpatrick, H; Waber, P; Hoa-Thai, T et al. (1997) Infrequency of BRCA2 alterations in head and neck squamous cell carcinoma. Oncogene 14:2189-93
Spillman, M A; Bowcock, A M (1996) BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. Oncogene 13:1639-45
Wu, L C; Wang, Z W; Tsan, J T et al. (1996) Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 14:430-40
Couch, F J; Castilla, L H; Xu, J et al. (1995) A YAC-, P1-, and cosmid-based physical map of the BRCA1 region on chromosome 17q21. Genomics 25:264-73

Showing the most recent 10 out of 12 publications